Modality
Peptide
MOA
BCL-2i
Target
Tau
Pathway
Innate Imm
CRCWilms
Development Pipeline
Preclinical
~Oct 2009
→ ~Jan 2011
Phase 1
~Apr 2011
→ ~Jul 2012
Phase 2
~Oct 2012
→ ~Jan 2014
Phase 3
~Apr 2014
→ ~Jul 2015
NDA/BLA
~Oct 2015
→ ~Jan 2017
Approved
Apr 2017
→ Jul 2030
ApprovedCurrent
NCT03326700
1,011 pts·CRC
2024-09→2028-04·Completed
NCT07488696
1,680 pts·Wilms
2017-04→2026-10·Active
NCT05693685
2,531 pts·CRC
2023-02→2028-02·Terminated
+1 more trial
6,449 total pts2 indications
CompletedCurrentUpcoming
Catalysts (4)
2026-10-146mo awayPh3 Readout· Wilms
2028-02-171.9y awayPh3 Readout· CRC
2028-04-192.1y awayPh3 Readout· CRC
2030-07-034.3y awayPh3 Readout· CRC
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Active
Approved
Recruit…
Approved
Termina…
Approved
Complet…
Catalysts
Ph3 Readout
2026-10-14 · 6mo away
Wilms
Ph3 Readout
2028-02-17 · 1.9y away
CRC
Ph3 Readout
2028-04-19 · 2.1y away
CRC
Ph3 Readout
2030-07-03 · 4.3y away
CRC
RecruitingActiveCompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03326700 | Approved | CRC | Completed | 1011 | VA |
| NCT07488696 | Approved | Wilms | Active | 1680 | BodyWt |
| NCT05693685 | Approved | CRC | Terminated | 2531 | BodyWt |
| NCT05777556 | Approved | CRC | Recruiting | 1227 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 |